Compare
NewAmsterdam Pharma Co N.V. vs Alumis Inc. vs CASI Pharmaceuticals, Inc. vs Evofem Biosciences, Inc.
| Latest fiscal year | NewAmsterdam Pharma Co N.V. NAMS | Alumis Inc. ALMS | CASI Pharmaceuticals, Inc. CASIF | Evofem Biosciences, Inc. EVFM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $22.50M | $24.05M | $20.71M | $20.18M |
| Revenue growth (YoY) | -50.6% | n/a | -27.4% | +4.2% |
| Gross margin | n/a | n/a | 48.6% | 77.1% (computed) |
| Operating margin | n/m | n/m | -217.3% | 16.7% |
| Net margin | -905.7% | n/m | -232.0% | 1.9% |
| Net income | -$203.82M | -$243.32M | -$48.06M | $391.0K |
| EPS (Diluted) | -$1.72 | -$2.86 | -$2.59 | $0.00 |
| Operating cash flow | -$147.78M | -$369.52M | -$20.75M | -$1.99M |
| Free cash flow | -$148.03M | -$370.18M | -$20.77M | -$2.00M |
| Cash & equivalents | $490.00M | $89.67M | $5.63M | $578.0K |
| Total assets | $769.28M | $411.94M | $25.65M | $20.27M |
| Total liabilities | $85.85M | $110.64M | $62.93M | $89.71M |
| Shareholders' equity | $683.43M | $301.30M | -$37.28M | -$74.34M |
| Return on year-end equity | -29.8% | -80.8% | n/a | n/a |
| Shares outstanding | 114.40M | n/a | 20.56M | 126.69M |
Revenue, most recent five fiscal years
| Fiscal year | NewAmsterdam Pharma Co N.V. | Alumis Inc. | CASI Pharmaceuticals, Inc. | Evofem Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $22.50M Ended 2025-12-31 | $24.05M Ended 2025-12-31 | $20.71M Ended 2025-12-31 | $20.18M Ended 2025-12-31 |
| 1 year earlier | $45.56M Ended 2024-12-31 | n/a | $28.54M Ended 2024-12-31 | $19.36M Ended 2024-12-31 |
| 2 years earlier | $14.09M Ended 2023-12-31 | n/a | $33.88M Ended 2023-12-31 | $18.22M Ended 2023-12-31 |
| 3 years earlier | $102.69M Ended 2022-12-31 | n/a | $43.11M Ended 2022-12-31 | $16.84M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $30.17M Ended 2021-12-31 | $8.24M Ended 2021-12-31 |